Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F139 - Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events

Monday, February 19; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize different forms of cutaneous adverse reactions and uncommon side effects of dermatologic medications.
  • Manage patients with dermatologic adverse reactions and develop evaluation and treatment plans based on reaction type.
  • Determine the most likely causative medications for specific cutaneous adverse reactions.


Dermatologists are frequently called upon to diagnose and manage patients with suspected drug rashes. With the pace of new medication development, it is important but difficult to keep up with the spectrum of side effects relevant to dermatology. This case-based interactive session will explore dermatologic adverse events. This will include cutaneous adverse reactions of non-dermatologic medications, as well as rare potential side effects of medications commonly prescribed by dermatologists. Cases will be selected that illustrate the clinical presentation, differential diagnosis, workup, and management of a variety of cutaneous adverse reactions and dermatologic drug side effects. This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.


  • Callen, Jeffrey Phillip, MD: 3M Pharmaceuticals – SH(ST); Abbott Laboratories – SH(ST); AbbVie – SH(ST); Allergan, Inc – SH(ST); Celgene – SH(ST); Johnson and Johnson – SH(ST); Merck & Co., Inc – SH(ST); Pfizer Inc. – SH(ST); Principia Biopharma Inc – Data Safety Monitoring Board(H); Procter & Gamble Company – SH(ST); UpToDate, Inc. – B(H);
  • Hunt, Raegan D., MD, PhD: no financial relationships exist with commercial interests.
  • Jung, Jae, MD, PhD: Adgero Biopharmaceuticals Holdings, Inc. – C(H); Amgen – C(H); Merck & Co., Inc – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding);
  • Owen, Cindy, MD: AbbVie – I(Grants/Research Funding); Accuitis, Inc – I(Grants/Research Funding); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Bristol-Myers Squibb – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Galderma USA – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Sol-Gel Technologies – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding);
Monday, February 19
3:30 PM
Dr. Owen / introduction and case presentation
4:00 PM
Dr. Hunt / case presentations
4:30 PM
Dr. Jung / case presentations
5:00 PM
Dr. Callen / case presentations
Event Details
  • Date
    Monday, February 19
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 25C
  • CME Credits
  • Type
  • Cindy Owen, MD, FAAD